Cambridge Healthtech Institute’s 3rd Annual

Oncolytic Virus Immunotherapy

Commercializing the Exciting Potential of Oncolytic Virotherapy

August 27-28, 2018

Oncolytic virotherapy (OV) represents an exciting new area of cancer treatment by exploiting a virus’s ability to selectively replicate and kill tumor tissue while stimulating a patient-specific immune response against cancer. Interest in the field is at an all-time high following significant deals and developments by Pfizer, Celgene and Amgen, to name but a few, plus scientific developments in using OV in combination studies.

CHI’s Oncolytic Virus Immunotherapy conference brings together leading industry and academic leaders to discuss the critical steps needed to accelerate oncolytic virus immunotherapy, from delivery to combination therapy strategies, virus engineering to critical product updates.


Preliminary Agenda

CURRENT PROGRESS AND FUTURE DIRECTIONS

KEYNOTE PRESENTATION: Unlocking the Full Potential of Cancer Immunotherapy

David Kirn, MD, Co-Founder & Executive Chairman, IGNITE Immunotherapy

Multiply Armed HSV-Based Immulytics for the Treatment of Cancer, Both Alone & in Combination with Immune Checkpoint Blockade

Robert Coffin, PhD, Co-Founder and CEO, Replimune

Novel Micro-RNA Attenuated Oncolytic HSV Virus with Combinatorial Immune Payloads for the Treatment of Metastatic Cancer

Christophe Queva, PhD, CSO, Oncorus

Progress with Oncolytic Vesicular Stomatitis Viruses

Stephen J. Russell, MD, PhD, CEO, Vyriad, Inc.

Talk Title to be Announced

Gunnar Kaufmann, PhD, Senior Vice President, Immunotherapy, Sorrento Therapeutics

Enadenotucirev: An Adenovirus with Vector for Therapeutic Transgenes

Charles Morris, PhD, CDO, Psioxus

Improving OV Potency, Targeting and Efficacy

Gabriella Campadelli, PhD, Co-Founder, Nouscom

Treatment with Conditionally Lytic Retroviral Replicating Vector Toca 511 Leads to Long Term Survival in Recurrent High Grade Glioma Patients

Douglas Jolly, PhD, Executive Vice President, R&D, Tocagen, Inc.

Development and Characterization of Novel Micro-RNA Attenuated Oncolytic Herpes Simplex Viruses

Michael Paglia, MSc, Vice President, CMC Operations, Oncorus

Designing Clinical Trials to Elucidate Oncolytic Virus Mechanisms-of-Action

Caroline Breitbach, PhD, Vice President, Translational Development, Turnstone Biologics

The T-Stealth Oncolytic Immunotherapy Platform

Matthew Mulvey, PhD, CEO, BeneVir Biopharm, Inc.

ProImmuneTalk Title to be Announced

Emilee Knowlton, Immunology Sales Specialist, Sales, ProImmune, Inc.

BIA separationsTalk Title to be Announced

Ales Strancar, Managing Director, BIA Separations




For more details on the conference, please contact:
Daniel Barry
Senior Conference Director
Cambridge Healthtech Institute
Email: dbarry@healthtech.com


For partnering and sponsorship information, please contact:
Rod Eymael,
Manager, Business Development,
Cambridge Healthtech Institute,
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com

#IOSummit